News

January 11, 2018January 11, 2018

FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eisai’s Lenvima (lenvatinib), in combination with Merck’s Keytruda (pembrolizumab), to treat patients with advanced renal cell carcinoma (RCC). The ... Read more

January 10, 2018

Lycera Starts Phase 1b Trial of Non-small Cell Lung Cancer Combo Therapy

News

Lycera has started a Phase 1b clinical trial to assess the safety of a combination of its immunotherapy LYC-55716 and Merck’s Keytruda (pembrolizumab) as a lung cancer therapy. The trial will involve patients whose non-small cell ... Read more

January 9, 2018January 9, 2018

Initial Safety Review Supports Expansion of MAGE-A10 SPEAR T-Cell Triple Tumor Phase 1 Trial

News

An initial review of two ongoing Phase 1 trials evaluating SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and in bladder, melanoma, and head and neck cancers, revealed ... Read more

January 8, 2018

Targovax’s Cancer Immunotherapy TG02 Is Safe, Initial Trial Review Shows

News

Targovax’s immunotherapy for solid tumors has passed its first clinical trial safety review. The company is conducting a Phase 1b trial of TG02 alone, and in combination with Merck’s Keytruda (pembrolizumab), as a treatment for ... Read more

January 5, 2018

Japan Approves Keytruda for Patients with Advanced Urothelial Carcinoma

News

Keytruda (pembrolizumab) was approved in Japan for the treatment of patients with radically unresectable (cannot be removed with surgery) urothelial carcinoma whose disease deteriorated after chemotherapy, Merck recently announced. Keytruda is ... Read more

January 4, 2018

First Patient Dosed in Phase 3 Trial of BeiGene’s Therapy Candidate for Advanced Liver Cancer

News

Investigators have dosed the first patient in a global Phase 3 trial evaluating the PD-1 inhibitor tislelizumab (BGB-A317) as a first-line therapy for advanced hepatocellular carcinoma (HCC) — the most common ... Read more

January 3, 2018

Opdivo Approved to Prevent Recurrence in Advanced Melanoma Patients

News

The U.S. Food and Drug Administration (FDA) has agreed that Opdivo (nivolumab) can be used as an adjuvant treatment of certain melanoma patients, to prevent their cancer from returning. The ... Read more

January 2, 2018

Nanobiotix Gets FDA Nod to Start Phase 1/2 Trial of NBTXR3 in Head and Neck, Lung Cancers

News

Nanobiotix will soon initiate a Phase 1/2 trial of NBTXR3 in combination with an anti-PD-1 antibody — Bristol-Myers Squibb’s Opdivo (nivolumab) or Merck’s Keytruda (pembrolizumab) — in patients with advanced head and neck ... Read more

December 22, 2017December 22, 2017

Phase 1b Trial to Test TAR-200, Opdivo Combo as Treatment for Muscle Invasive Bladder Cancer

News

A new Phase 1b clinical trial will evaluate if combining TAR-200 (GemRIS), a chemotherapy-releasing agent, and Opdivo (nivolumab) is a safe, well tolerated, and efficacious approach for the treatment of muscle invasive ... Read more

December 21, 2017

Halting TGF-β Activity May Reduce Resistance to Checkpoint Inhibitors, Study Shows

News

An analysis of tumor samples collected during the IMvigor210 Phase 2 clinical trial has revealed a mechanism of cancer cell resistance to immune checkpoint inhibitors like Tecentriq (atezolizumab). The findings will help ... Read more